Colorectal cancer
Conditions
Interventions
Apatinib treatment group:Apatinib Tablets orally
Sponsors
Xinqiao Hospital, Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with advanced and / or metastatic colorectal cancer confirmed by pathology; 2. Patients must have at least 1 lesion that is measurable using RECIST v1.1 criteria; 3. Patients receiving first-line chemotherapy and without progression (who are unable to tolerate chemotherapy toxicity can also be treated, but should be evaluated for progression); 4. Aged >18years old, both genders; 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 2; 6. Life expectancy of more than 3 months; 7. Organ functional levels meeting the following criteria: Blood routine: hemoglobin = 80g / L, absolute neutrophil count (ANC) = 1.5×10^9/L, platelet = 90×10^9/L; Blood biochemical: ALT, AST = 2.5 × ULN, if the liver metastasis = 5×ULN, serum total bilirubin = 1.5 × ULN, SCr (serum creatinine) <1.5×ULN, serum albumin = 30g/L; 8. participants volunteered to participate in this study, signed informed consent, compliance, with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with high blood pressure and who can not be reduced to normal range by antihypertensive therapy (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg), with grade I coronary heart disease, grade I arrhythmia (including QTc prolongation > 470 ms) and grade I cardiac insufficiency; 2. There are several factors that affect oral medicine, such as unable to swallow, uncontrollable nausea and vomitin, or chronic diarrhea and intestinal obstruction; 3. Patients with clear bleeding tendency; 4. Imaging shows that the tumor has violated the important vascular.According to the judgement of investigator,patients in high risk of invasion of vital blood vessels will be caused by fatal bleeding during treatment; 5. Patients with the history of HIV (human immunodeficiency virus) infection; 6. History of abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 month prior to study entry; 7. patients with positive urine protein; 8. Patients with active brain metastasis; 9. Patients with other malignancies within 5 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix; 10. Pregnant or lactating women; 11. According to the researcher's judgment, the patients with a serious risk of compromising the patient's safety or affecting the patient's completion of the study can not be allowed to entry the trail; 12. Researchers believe that they are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;DCR; | — |
Countries
China
Contacts
Public ContactXiao Weidong
Xinqiao Hospital, Chongqing
Outcome results
None listed